who should not take glp-1 receptor agonists Mapping the effectiveness and risks of GLP-1 Receptor Agonists in Solid

Case reports

The authors conclude: In this real-world study where half of patients discontinued GLP-1-based treatment within a year after initiation, not losing weight was associated with worse clinical outcomes while larger reductions were associated with decreased risks

A growing array of treatment modalities and new entrants are crowding the market, with biotech companies promoting next-generation GLP-1 candidates alongside established pharmaceutical players

Let's talk more heart health

Approximately 70% of women diagnosed with ovulatory disorders have polycystic ovarian syndrome (PCOS)

Accordingly, many of the neuroprotective mechanisms outlined in the discussion of DR have implications for glaucoma as well